Enlivex Therapeutics Stock Performance
| ENLV Stock | USD 1.10 0.01 0.90% |
The firm shows a Beta (market volatility) of -0.28, which means not very significant fluctuations relative to the market. As returns on the market increase, returns on owning Enlivex Therapeutics are expected to decrease at a much lower rate. During the bear market, Enlivex Therapeutics is likely to outperform the market. At this point, Enlivex Therapeutics has a negative expected return of -0.15%. Please make sure to confirm Enlivex Therapeutics' standard deviation, potential upside, as well as the relationship between the Potential Upside and day median price , to decide if Enlivex Therapeutics performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Enlivex Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of latest weak performance, the Stock's essential indicators remain stable and the latest fuss on Wall Street may also be a sign of long-term gains for the venture sophisticated investors. ...more
Last Split Factor 1:8 | Dividend Date 2019-03-06 | Last Split Date 2019-03-06 |
1 | Enlivex Launches Phase I Trial for Novel Psoriatic Arthritis Treatment Allocetra - StockTitan | 11/14/2024 |
2 | Enlivex Adopts Bitcoin Treasury Reserve Strategy | 11/20/2024 |
3 | Enlivex Therapeutics Faces Financial Challenges Amid Losses - TipRanks | 11/29/2024 |
4 | Enlivex Receives Regulatory Authorization for the Initiation of a Phase I Trial Evaluating Allocetra in Patients with TMJ Osteoarthritis | 12/11/2024 |
5 | Enlivex Therapeutics and bioAffinity Technologies Interviews to Air on the RedChip Small Stocks, Big Money Show on Bloomberg TV | 01/10/2025 |
| Begin Period Cash Flow | 50.4 M | |
| Free Cash Flow | -23.8 M |
Enlivex |
Enlivex Therapeutics Relative Risk vs. Return Landscape
If you would invest 130.00 in Enlivex Therapeutics on November 2, 2024 and sell it today you would lose (19.00) from holding Enlivex Therapeutics or give up 14.62% of portfolio value over 90 days. Enlivex Therapeutics is currently does not generate positive expected returns and assumes 4.9804% risk (volatility on return distribution) over the 90 days horizon. In different words, 44% of stocks are less volatile than Enlivex, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Enlivex Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Enlivex Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Enlivex Therapeutics, and traders can use it to determine the average amount a Enlivex Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0301
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | ENLV |
Estimated Market Risk
| 4.98 actual daily | 44 56% of assets are more volatile |
Expected Return
| -0.15 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.03 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Enlivex Therapeutics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Enlivex Therapeutics by adding Enlivex Therapeutics to a well-diversified portfolio.
Enlivex Therapeutics Fundamentals Growth
Enlivex Stock prices reflect investors' perceptions of the future prospects and financial health of Enlivex Therapeutics, and Enlivex Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Enlivex Stock performance.
| Return On Equity | -0.61 | ||||
| Return On Asset | -0.27 | ||||
| Current Valuation | 646.39 K | ||||
| Shares Outstanding | 21.99 M | ||||
| Price To Earning | (11.97) X | ||||
| Price To Book | 0.92 X | ||||
| EBITDA | (28.22 M) | ||||
| Net Income | (29.07 M) | ||||
| Cash And Equivalents | 62.48 M | ||||
| Cash Per Share | 3.40 X | ||||
| Total Debt | 1.03 M | ||||
| Debt To Equity | 0.08 % | ||||
| Current Ratio | 15.44 X | ||||
| Book Value Per Share | 1.62 X | ||||
| Cash Flow From Operations | (23.52 M) | ||||
| Earnings Per Share | (0.98) X | ||||
| Market Capitalization | 24.41 M | ||||
| Total Asset | 36.83 M | ||||
| Retained Earnings | (112.09 M) | ||||
| Working Capital | 27.7 M | ||||
| Current Asset | 6 M | ||||
| Current Liabilities | 671.32 K | ||||
About Enlivex Therapeutics Performance
Evaluating Enlivex Therapeutics' performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Enlivex Therapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Enlivex Therapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 497.61 | 522.49 | |
| Return On Tangible Assets | (0.71) | (0.75) | |
| Return On Capital Employed | (0.86) | (0.90) | |
| Return On Assets | (0.71) | (0.75) | |
| Return On Equity | (0.87) | (0.91) |
Things to note about Enlivex Therapeutics performance evaluation
Checking the ongoing alerts about Enlivex Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Enlivex Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Enlivex Therapeutics generated a negative expected return over the last 90 days | |
| Enlivex Therapeutics may become a speculative penny stock | |
| Enlivex Therapeutics has high historical volatility and very poor performance | |
| Net Loss for the year was (29.07 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Enlivex Therapeutics currently holds about 62.48 M in cash with (23.52 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.4, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Latest headline from finance.yahoo.com: Enlivex Therapeutics and bioAffinity Technologies Interviews to Air on the RedChip Small Stocks, Big Money Show on Bloomberg TV |
- Analyzing Enlivex Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Enlivex Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Enlivex Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Enlivex Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Enlivex Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Enlivex Therapeutics' stock. These opinions can provide insight into Enlivex Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Enlivex Stock Analysis
When running Enlivex Therapeutics' price analysis, check to measure Enlivex Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Enlivex Therapeutics is operating at the current time. Most of Enlivex Therapeutics' value examination focuses on studying past and present price action to predict the probability of Enlivex Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Enlivex Therapeutics' price. Additionally, you may evaluate how the addition of Enlivex Therapeutics to your portfolios can decrease your overall portfolio volatility.